紫杉醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性研究

摘要

目的：研究紫杉醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性。方法：将90例晚期卵巢癌患者纳入研究，采用随机数表法分为观察组和对照组，观察组给予紫杉醇135 mg/m2、奈达铂80 mg/m2静脉滴注；对照组给予紫杉醇135 mg/m2、顺铂20 mg/m2静脉滴注。观察患者化疗效果、不良反应以及远期存活情况。结果：①观察组患者的TNM分期、VEGFA和VEGFB含量均低于对照组；②观察组患者发生厌食、恶心呕吐、白细胞减少、血小板减少、血肌酐升高、ALT升高及肺毒性的例数均少于对照组；③术后1年、2年和3年时观察组患者的存活率高于对照组。结论：紫杉醇联合奈达铂能够取得显著的化疗效果，并可减少不良反应，延长存活时间，是极为高效、低毒的化疗方案。%Objective: To study the effect and safety of paclitaxel combined with different platinum chemotherapy in treating advanced ovarian cancer. Methods:advanced ovarian cancer patients in our hospital from June 2008 to June 2009 were enrolled and divided into observation group according to random number table. Observation group given 135 mg/m2 paclitaxel and 80 mg/m2 nedaplatin;control group given 135 mg/m2 paclitaxel and 20 mg/m2 cisplatin. Then chemotherapy effect, toxicity and long-term survival condition were observed. Results:(1)TNM stage and VEGFA, VEGFB content of observation group were lower than those of control group;(2)cases of anorexia, nausea and vomiting, leukopenia, thrombocytopenia, increasing serum creatinine, elevated ALT, pulmonary toxicity were lower than those of control group;(3)1 years, 2 years, 3 years after chemotherapy, survival cases of observation group were more than those of control group. Conclusion:Paclitaxel combined with nedaplatin are more efficient and low toxic chemotherapy for it can achieve more exact effect and reduce side effects.